CNF combination as adjuvant treatment in breast cancer patients is well tolerated

被引：7

作者：

Hirvikoski, PP ^{[1
]}

Kumpulainen, EJ ^{[1
]}

Johansson, RT ^{[1
]}

机构：

[1] KUOPIO UNIV HOSP,DEPT ONCOL,SF-70211 KUOPIO,FINLAND

来源：

ANTI-CANCER DRUGS | 1997年 / 8卷 / 04期

关键词：

adjuvant; breast; chemotherapy; cyclophosphamide; fluorouracil; neoplasm; mitoxantrone; side effects;

D O I：

10.1097/00001813-199704000-00010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

in this study 194 women with breast cancer received adjuvant CNF combination therapy (cyclophosphamide, mitoxantrone and 5-fluorouracil), The side effects and acute toxicity of the regimen were recorded, Although myelosuppression is the dose-limiting factor of the CNF regimen, it was well tolerated and side effects were limited. This regimen induced no cardiotoxicity or irreversible alopecia. It is concluded that CNF is suitable as adjuvant chemotherapy for breast cancer patients.

引用

页码：376 / 378

页数：3

共 14 条

[1] A RANDOMIZED MULTICENTER TRIAL COMPARING MITOXANTRONE, CYCLOPHOSPHAMIDE, AND FLUOROURACIL WITH DOXORUBICIN, CYCLOPHOSPHAMIDE, AND FLUOROURACIL IN THE THERAPY OF METASTATIC BREAST-CARCINOMA
BENNETT, JM
MUSS, HB
DOROSHOW, JH
WOLFF, S
KREMENTZ, ET
CARTWRIGHT, K
DUKART, G
REISMAN, A
SCHOCH, I
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) : 1611 - 1620
[2] CARPENTER JT, 1994, P AN M AM SOC CLIN, V13, pA68
[3] *EARL BREAST CANC, 1992, LANCET, V339, P71
[4] EFFECT OF SYSTEMIC ADJUVANT TREATMENT ON FIRST SITES OF BREAST-CANCER RELAPSE
GOLDHIRSCH, A
GELBER, RD
PRICE, KN
CASTIGLIONE, M
COATES, AS
RUDENSTAM, CM
COLLINS, J
LINDTNER, J
HACKING, A
MARINI, G
BYRNE, M
CORTESFUNES, H
SCHNURCH, G
BRUNNER, KW
TATTERSALL, MHN
FORBES, J
SENN, HJ
[J]. LANCET, 1994, 343 (8894) : 377 - 381
[5] HENDERSON IG, 1992, BREAST DIS, P427
[6] HOLMES FA, 1987, CANCER-AM CANCER SOC, V59, P1992, DOI 10.1002/1097-0142(19870615)59:12<1992::AID-CNCR2820591204>3.0.CO
[7] 2-V
[8] HORTOBAGYI GN, 1986, NATL CANCER I MONOGR, V1, P105
[9] A PRELIMINARY-REPORT OF A PILOT RANDOMIZED TRIAL COMPARING CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL WITH CYCLOPHOSPHAMIDE, MITOXANTRONE AND 5-FLUOROURACIL IN THE ADJUVANT THERAPY OF STAGE-II BREAST-CANCER WITH 4 OR MORE POSITIVE AXILLARY NODES
ISACSON, R
SAFRA, T
BENDOR, CG
UZIELY, B
BRUFMAN, G
[J]. ANTI-CANCER DRUGS, 1993, 4 (02) : 189 - 192
[10] MARTY M, 1994, P AN M AM SOC CLIN, V13, pA50

← 1 2 →